From IKE
Jump to: navigation, search

Spironolactone is a pharmacological agent recently rediscovered in the care of patients with severe heart failure for its effects on on morbidity and mortality. A study of the effects found a 30% risk reduction from both pump failure and sudden death, and a 35% reduction in hospitalization frequency, with concommitant improvement in symptoms.